var title_f2_52_2880="Glucagon injection sites child PI";
var content_f2_52_2880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Where to give a child a glucagon shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A glucagon shot can be given in the side of the belly, upper arm, or upper leg (as shown by the shaded areas).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2880=[""].join("\n");
var outline_f2_52_2880=null;
var title_f2_52_2881="Harlequin fetus";
var content_f2_52_2881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Harlequin fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ichthyosis in a harlequin fetus with massive thickening of the keratin layer, which cracks to form fissures between thickened plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2881=[""].join("\n");
var outline_f2_52_2881=null;
var title_f2_52_2882="Sinus biopsy 1B answer";
var content_f2_52_2882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucor on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mold Mucor exhibits an exuberant, cottony appearance when grown on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2882=[""].join("\n");
var outline_f2_52_2882=null;
var title_f2_52_2883="En coup de sabre - alopecia";
var content_f2_52_2883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    En coup de sabre with secondary alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A shiny, linear, hypopigmented and hyperpigmented sclerotic plaque is present on the forehead and scalp in this patient with en coup de sabre. Note the presence of secondary alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2883=[""].join("\n");
var outline_f2_52_2883=null;
var title_f2_52_2884="Forced air rewarming";
var content_f2_52_2884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forced air rewarming",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Child in a forced air warming device.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hickey R, de Caen A. Warming procedures. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2884=[""].join("\n");
var outline_f2_52_2884=null;
var title_f2_52_2885="Conjunctival scarring";
var content_f2_52_2885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cicatricial disease: conjunctival scarring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) WHO grade TS (trachomatous conjunctival scarring). To make a diagnosis of TS, there must be evidence of scars on the tarsal conjunctiva. Initially thin discrete white lines appear to transverse the conjunctiva (as indicated by the arrows). B) Arlt's line. As scarring progresses, conjunctival tissue coalesces, forming a thick white band near the lid margin known as Arlt's line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2885=[""].join("\n");
var outline_f2_52_2885=null;
var title_f2_52_2886="Chapter 9B: Renal water excretion and reabsorption";
var content_f2_52_2886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 9B: Renal water excretion and reabsorption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2886/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/52/2886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the kidney, the bulk of the filtered water is reabsorbed passively in the proximal tubule and descending limb of the loop of Henle down an osmotic gradient created by NaCl transport. This serves to maintain the volume of the extracellular fluid. In addition, the kidney contributes to the stability of the Posm &nbsp;by excreting or reabsorbing water without solute. This function is primarily mediated by the presence (water conservation, high urine osmolality [Uosm ]) or absence (water excretion, low Uosm) of ADH. In normal adults, the Uosm can vary from a minimum of 40 to 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/1\">",
"     1",
"    </a>",
"    ] to a maximum of 900 to 1400",
"    <span class=\"nowrap\">",
"     mosmol/kg&dagger;",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/2\">",
"     2",
"    </a>",
"    ]. A review of the mechanisms of dilution and concentration can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &dagger; Concentrating ability tends to fall with age, as the maximum Uosm in an elderly patient may be only 500 to 700",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Why this occurs is not well understood.",
"   </p>",
"   <p>",
"    The quantitative importance of ADH on water excretion is depicted in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef65785 \" href=\"UTD.htm?5/25/5531\">",
"     table 1",
"    </a>",
"    ). In a subject excreting 800 mosmol of solute per day, the urine volume can vary 15-fold, depending upon the availability of ADH. In the absence of ADH, for example, the minimum Uosm may be 80",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    resulting in the excretion of the 800 mosmol of solute in 10 liters of water. In a normal subject, this degree of polyuria is rarely seen and occurs only after a massive water load. More commonly, there is a moderate amount of ADH present, and the Uosm is somewhere between the extremes of 80",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (no ADH) and 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (maximum ADH). If this subject had to excrete 2000 mL of water to remain in water balance, the average Uosm would be 400",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    that is, 800 mosmol of solute in 2000 mL. This would require a submaximal ADH effect.",
"   </p>",
"   <p>",
"    The urine output also is affected by solute excretion, which is equal to net solute intake in the steady state. This is particularly important in disorders in which the rate of ADH secretion is relatively constant (",
"    <a class=\"graphic graphic_figure graphicRef52379 \" href=\"UTD.htm?2/47/2815\">",
"     figure 1",
"    </a>",
"    ). In a patient with complete central diabetes insipidus, for example, there is little or no ADH and the maximum Uosm may be only 80",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    In this setting, the daily urine volume will 10 liters if 800 mosmol of solute is excreted, but only 5 liters if 400 mosmol of solute is excreted (400 mosmol of solute at 80",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    equals 5 L of urine). Thus, one form of therapy is to restrict the intake of sodium and protein (which is metabolized to urea); the ensuing reduction in solute excretion will then limit the degree of polyuria. Dietary modification may be especially important in patients with nephrogenic diabetes insipidus, who are resistant to the action of ADH and who therefore will not respond to hormone administration (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF RENAL WATER EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This simple example of the effect of solute excretion demonstrates that water excretion can vary widely without changes in the Uosm. Thus, the Uosm , which reflects the kidney's ability to dilute or concentrate the urine, is not an accurate estimate of its quantitative ability to excrete or retain water.",
"   </p>",
"   <p>",
"    To measure the amount of solute-free water that the kidney can excrete per unit time, one can calculate the free-water clearance, CH2O. If the urine is hypoosmotic to plasma, the total urine volume (V, in",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     L/day)",
"    </span>",
"    can be viewed as having two components: one that contains all the urinary solute in a solution that is isosmotic to plasma (the osmolal clearance, or Cosm); and one that contains the solute-free water that makes the urine dilute (the free-water clearance) (",
"    <a class=\"graphic graphic_figure graphicRef76658 \" href=\"UTD.htm?13/20/13645\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/4\">",
"     4",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;V &nbsp; = &nbsp; &nbsp; Cosm &nbsp; + &nbsp; CH2O",
"   </p>",
"   <p>",
"    The Cosm can be calculated from the general formula for clearance, C &nbsp;=",
"    <span class=\"nowrap\">",
"     UV/P",
"    </span>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=see_link\">",
"     \"Chapter 2E: Clinical evaluation of the renal circulation\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;Cosm &nbsp; &nbsp;= &nbsp; (Uosm &nbsp; x &nbsp; V) &nbsp; &divide; &nbsp; Posm",
"   </p>",
"   <p>",
"    If Eq. (1) is now solved for the CH2O, then",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp;CH2O &nbsp; &nbsp;= &nbsp; V &nbsp;- &nbsp;Cosm",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; &nbsp; V &nbsp; x &nbsp; (1 &nbsp;- &nbsp;[Uosm &divide; Posm])",
"   </p>",
"   <p>",
"    The manner in which this formula is used can be illustrated if we return to the patient with central diabetes insipidus who is excreting a maximally dilute urine. If",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Posm &nbsp; &nbsp;= &nbsp; &nbsp; 280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Uosm &nbsp; = &nbsp; &nbsp; 80",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;V &nbsp; &nbsp; &nbsp;= &nbsp; 10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    then",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;CH2O &nbsp; &nbsp;= &nbsp; &nbsp; 10 (1 &nbsp;- &nbsp;[80 &divide; 280]) &nbsp; &nbsp;= &nbsp; &nbsp;7.2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    Thus, of the 10 liters of urine being excreted, 7.2 liters exists as free water (CH2O) and 2.8 liters as an isosmotic solution containing all of the urinary solute (Cosm).",
"   </p>",
"   <p>",
"    In the clinical setting, the excretion of large volumes of dilute urine may be appropriate if it follows a water load or inappropriate if it is due to a primary deficiency of ADH or renal resistance to its effects. In either case, the loss of solute-free water tends to raise the Posm and plasma Na+ concentration unless accompanied by an equivalent increase in water intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physiologic Factors Affecting CH2O",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excretion of free water by the kidney occurs in two basic steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Solute-free water is generated by NaCl reabsorption without water in the medullary and cortical aspects of the ascending limb of the loop of Henle and to a lesser degree in the distal nephron.",
"     </li>",
"     <li>",
"      This water is then excreted by keeping the collecting tubules relatively impermeable to water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In normal subjects, the volume of free water generated in the loop of Henle (step 1) is primarily dependent upon the volume of water presented to that segment. Collecting tubular impermeability to water (step 2), on the other hand, requires the absence of ADH.",
"   </p>",
"   <p>",
"    An understanding of the factors that influence CH2O has important clinical implications in patients with hyponatremia and hypoosmolality. Since the capacity for water excretion is normally so great (as much as 10 to 20",
"    <span class=\"nowrap\">",
"     L/day),",
"    </span>",
"    water retention leading to hyponatremia will occur only if there is a defect in water excretion or rarely if the amount of water ingested exceeds excretory capacity. Diminished water excretion requires that one or both of the steps described above are impaired. This can occur in three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If less free water is generated because the rate of fluid delivery to the loop of Henle is reduced, as with oliguric renal failure (where less water is filtered) or volume depletion (where less water may be filtered and more is reabsorbed in the proximal tubule).",
"     </li>",
"     <li>",
"      If less free water is generated because NaCl reabsorption is inhibited by diuretics, particularly the thiazide-type diuretics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=see_link\">",
"       \"Diuretic-induced hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If ADH is present, as with volume depletion, the syndrome of inappropriate ADH secretion, hypothyroidism, or adrenal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders, with primary polydipsia in which there is a primary increase in water intake, constitute the entire differential diagnosis of true hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .) It is important to emphasize again that hyponatremia is a disorder of water, not Na+ imbalance. It is usually characterized by impaired water excretion, which lowers the plasma Na+ concentration by dilution. Urinary Na+ loss, on the other hand, directly causes effective circulating volume depletion. It can also be associated with hyponatremia if there is both a hypovolemic stimulus to ADH release and some water intake to allow water retention to occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF RENAL WATER REABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the formation of a dilute urine, the kidney is also able to excrete urine with an osmolality exceeding that of the plasma. If the urine is hyperosmotic, the urine volume can again be viewed as having two components: one containing all the urinary solute in an isosmotic solution; and one containing the amount of free water that must have been removed from the urine by tubular reabsorption to raise the Uosm to the observed hyperosmotic value (the free-water reabsorption; TcH2O). In this setting (",
"    <a class=\"graphic graphic_figure graphicRef55579 \" href=\"UTD.htm?14/55/15229\">",
"     figure 3",
"    </a>",
"    ),",
"   </p>",
"   <p>",
"    (Eq. 4) &nbsp; &nbsp;V &nbsp; = &nbsp; &nbsp; Cosm &nbsp; - &nbsp; TcH2O",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;TcH2O &nbsp; = &nbsp; &nbsp;Cosm &nbsp; &nbsp;- &nbsp; V",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; &nbsp;V &nbsp;([Uosm &nbsp;&divide; &nbsp;Posm] &nbsp;- &nbsp;1)",
"   </p>",
"   <p>",
"    In contrast to the CH2O, which is equal to the volume of free water excreted per unit time, the TCH2O is equal to the volume of free water reabsorbed per unit time. Suppose, for example, that a subject who has developed a mild water deficit puts out a concentrated urine and has the following values,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Posm &nbsp; &nbsp;= &nbsp; &nbsp; 290",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Uosm &nbsp; = &nbsp; &nbsp; 580",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; V &nbsp; &nbsp; = &nbsp; 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    In this setting",
"   </p>",
"   <p>",
"    (Eq. 5) &nbsp; &nbsp;TcH2O &nbsp; &nbsp;= &nbsp; &nbsp; 1 &nbsp; x &nbsp; ([580 &nbsp;&divide; &nbsp;290] &nbsp;- &nbsp;1) &nbsp; &nbsp;= &nbsp; 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    These values can also be used to calculate the CH2O:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;CH2O &nbsp; = &nbsp; &nbsp; 1 &nbsp; x &nbsp; &nbsp;(1 &nbsp;- &nbsp;[580 &nbsp;&divide; &nbsp;290]) &nbsp; &nbsp;= &nbsp; - 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    Thus, - 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    of free water is being excreted, another way of stating that 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    is being reabsorbed. This illustrates the inverse relationship between the CH2O, which measures free water excretion, and the TcH2O, which represents free water reabsorption:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;CH2O &nbsp; &nbsp;= &nbsp; &nbsp;- TcH2O",
"   </p>",
"   <p>",
"    These results suggest that 1 L of free water is being added to plasma, which is appropriate in that it tends to lower the plasma osmolality back toward normal. The net effect, however, is different if the elevation in ADH release responsible for the high Uosm is due to the syndrome of inappropriate ADH secretion. In this setting, the retention of 1 liters of water that would normally have been excreted will lead to hypoosmolality and hyponatremia. This illustrates the importance of thinking in terms of TcH2O rather than of only the Uosm. The latter merely indicates the presence of a concentrated urine; the former tells exactly how much water is being retained by the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electrolyte-free water reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formulas presented above described urinary water excretion in relation to total urinary solutes. This concept, however, must be amended when viewed in terms of the plasma Na+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/4\">",
"     4",
"    </a>",
"    ]. The plasma Na+ concentration is usually determined by the relationship between total exchangeable extracellular solutes (primarily Na+ salts), total exchangeable intracellular solutes (primarily K+ salts), and the total body water (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    (Eq. 6) &nbsp; &nbsp;Plasma [Na+] &nbsp; &asymp; &nbsp; (Nae+ &nbsp;+ &nbsp;Ke+)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    TBW",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 7A: Exchange of water between the cells and ECF\", section on 'Determinants of the Plasma Sodium Concentration'",
"    </a>",
"    .) Urea does not contribute to this relationship because it freely equilibrates across the cell membrane and therefore does not influence the effective Posm or the distribution of water between the cells and the extracellular fluid. However, urea is one of the major urinary solutes that can account for a large part of the Uosm. The loss of urea in the urine will cause the plasma urea concentration to fall but will not affect the plasma Na+ concentration. Similar considerations apply to the urinary excretion of ammonium.",
"   </p>",
"   <p>",
"    To more accurately assess the effect of the urine output on osmoregulation, the above formula for the TcH2O &nbsp;must be amended in the following ways: (1) UNa+ + K+ is substituted for the total Uosm ; and (2) the plasma Na+ concentration is substituted for the Posm. This new quantity is called the electrolyte-free water reabsorption or TeCH2O&dagger;:",
"   </p>",
"   <p>",
"    (Eq. 7) &nbsp; &nbsp;TeCH2O &nbsp; &nbsp;= &nbsp; V &nbsp; x &nbsp; [UNa+ + &nbsp;UK+] &nbsp;&divide; &nbsp;PNa+ &nbsp; - &nbsp; 1",
"   </p>",
"   <p>",
"    &nbsp;&dagger; This correction should also be applied to the formula for free water clearance in Eq. (3) to calculate the electrolyte-free water clearance, CeH2O.",
"   </p>",
"   <p>",
"    Suppose that the above patient with a fluid deficit and a urine osmolality of 580",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    had 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of Na+ and 43",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of K+ in the urine and had a plasma Na+ concentration of 144",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In this setting:",
"   </p>",
"   <p>",
"    (Eq. 8) &nbsp; &nbsp;TeCH2O &nbsp; &nbsp;= &nbsp; 1 &nbsp; x &nbsp;([48 &nbsp;&divide; &nbsp;144] &nbsp;- &nbsp;1) &nbsp; &nbsp;= &nbsp; - 670",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"   </p>",
"   <p>",
"    Thus, instead of retaining 1 L of free water as in Eq. (5), this subject actually has a negative value for the TeCH2O and is losing 670 mL of free water per day.",
"   </p>",
"   <p>",
"    This concept is extremely important, because it illustrates again the difference between the Uosm and exact measurement of how much water is actually being excreted or reabsorbed. The Uosm of 580",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in this patient indicates that ADH is present and is producing a relatively concentrated urine. This response is appropriate, since it limits further water loss, which would aggravate the already present water deficit. Use of the traditional formula for free water reabsorption in Eq. (5) suggests that this concentrated urine also results in the addition of 1 liter of free water to the body, directly correcting the mildly hyperosmolal state. However, the sum of Na+ plus K+ in the urine is less than that in the plasma. Thus, from the viewpoint of regulation of the plasma Na+ concentration, the urine output in this patient leads to the loss of 670 mL of free water (from Eq. (8)), producing a further tendency to hypernatremia. This finding should not suggest that ADH is ineffective, since the Uosm would be under 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and the urine volume above 5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in its absence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical example",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 78 year-old partially demented man is admitted to the hospital because of pneumonia. Hyperalimentation with high-protein supplements (containing 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    each of Na+ and K+) is begun in an attempt to improve the patient's somewhat poor nutritional status. Over the ensuing 5 days, it is noted that the urine output is averaging 4",
"    <span class=\"nowrap\">",
"     L/day,",
"    </span>",
"    the blood urea nitrogen (BUN) has risen from 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to 88",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the plasma creatinine concentration is relatively stable at 1.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and the plasma Na+ concentration has risen from 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    up to 156",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    despite a relatively high fluid intake. The following additional findings are obtained:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Posm &nbsp; &nbsp;= &nbsp; 342",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Uosm &nbsp; &nbsp;= &nbsp; 510",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;UNa+ &nbsp; &nbsp;= &nbsp; 10",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;UK+ &nbsp; &nbsp; &nbsp;= &nbsp; 42",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not initially clear how the hypernatremia developed in this patient, since the intake was relatively dilute and the urine concentrated. Using the traditional formula for free water reabsorption in Eq. (4), it appears that the kidney in this polyuric patient is actually adding 2 L of free water to the body per day, thereby protecting against the development of hypernatremia:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;TcH2O &nbsp; = &nbsp; &nbsp; 4 &nbsp; x &nbsp;( [510 &nbsp;&divide; &nbsp;342] &nbsp;- &nbsp;1) &nbsp; &nbsp;= &nbsp; 2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    However, this patient is polyuric because of a urea osmotic diuresis, in which the excretion of large quantities of urea (derived from the catabolism of the extra dietary protein) both raises the BUN and obligates the excretion of a large volume of urine. Once again, the urine contains relatively little Na+ and K+. If we use the formula for the electrolyte-free water reabsorption,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;TeCH2O &nbsp; &nbsp;= &nbsp; &nbsp; 4 ([52 &nbsp;&divide; &nbsp;156] &nbsp;- &nbsp;1) &nbsp; &nbsp;= &nbsp; - 2.7",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    the etiology of the hypernatremia is now apparent: the patient is losing approximately 2.7 L of free water per day in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiologic factors affecting free water reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal water conservation is dependent upon two basic steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The formation and maintenance of the medullary osmotic gradient",
"     </li>",
"     <li>",
"      Equilibration of the urine in the collecting tubules with the hyperosmotic medullary interstitium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ADH plays an important role in both steps by promoting the medullary accumulation of urea and by increasing the water permeability of the collecting tubules. Medullary hyperosmolality is also dependent upon NaCl reabsorption without water in the ascending limb of the loop of Henle, a process that in humans is probably independent of ADH.",
"   </p>",
"   <p>",
"    The concentrating process can be impaired by a defect in ADH release, decreased responsiveness of the collecting tubule epithelium to ADH (most often due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    use or hypercalcemia in adults), or a primary abnormality in countercurrent function, preventing the maintenance of the hyperosmotic interstitium. When one of these disturbances is present, water excretion increases and the patient may complain of polyuria and polydipsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .) Stimulation of thirst is an important protective response, since it can counteract the increased urinary losses, thereby preventing negative water balance and the eventual development of hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to excrete urine with an osmolality different from that of the plasma plays a central role in the regulation of water balance and maintenance of the Posm and the plasma Na+ concentration. If the Posm &nbsp;is decreased, e.g., after a water load, ADH secretion is inhibited. This results in the excretion of a dilute urine, which increases the Posm &nbsp;to normal. If the Posm &nbsp;is elevated, e.g., because of sweat loss, both ADH release and thirst are stimulated. The combination of diminished urinary water loss &nbsp;and enhanced water intake results in water retention and a decrease in Posm &nbsp;to normal.",
"   </p>",
"   <p>",
"    In addition to the urine osmolality, solute excretion also determines how much water can be excreted (",
"    <a class=\"graphic graphic_figure graphicRef52379 \" href=\"UTD.htm?2/47/2815\">",
"     figure 1",
"    </a>",
"    ). Thus, the quantity of free water excreted or reabsorbed is best measured directly as CeH2O or TeCH2O, rather than being inferred from the urine osmolality.",
"   </p>",
"   <p>",
"    Although the role of solute excretion may at first glance appear to be of interest only to the physiologist, it becomes clinically important in several situations. In normal subjects, water intake is the major determinant of the urine volume by its effect on ADH release. However, when ADH secretion or responsiveness is relatively fixed (as in the syndrome of inappropriate ADH secretion or diabetes insipidus), water intake no longer directly affects the urine volume and the rate of solute excretion assumes primary importance. As described above, restricting dietary NaCl and protein intake is one way to diminish the urine output and the secondary polydipsia in patients with nephrogenic diabetes insipidus, who are resistant to the effects of ADH.",
"   </p>",
"   <p>",
"    On the other hand, the syndrome of inappropriate ADH secretion is characterized by a reduction in the urine output and a tendency to water retention and hyponatremia. In this setting, a high-sodium, high-protein diet or the direct administration of urea in refractory cases can increase the urine output and raise the plasma Na+ concentration toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2886/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=see_link\">",
"     \"Chapter 10A: Acids and bases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2886/abstract/1\">",
"      SCHOEN EJ. Minimum urine total solute concentration in response to water loading in normal men. J Appl Physiol 1957; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2886/abstract/2\">",
"      LINDEMAN RD, VAN BUREN HC, RAISZ LG. Osmolar renal concentrating ability in healthy young men and hospitalized patients without renal disease. N Engl J Med 1960; 262:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2886/abstract/3\">",
"      SPORN IN, LANCESTREMERE RG, PAPPER S. Differential diagnosis of oliguria in aged patients. N Engl J Med 1962; 267:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2886/abstract/4\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7259 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2886=[""].join("\n");
var outline_f2_52_2886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASUREMENT OF RENAL WATER EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physiologic Factors Affecting CH2O",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEASUREMENT OF RENAL WATER REABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electrolyte-free water reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical example",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Comment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiologic factors affecting free water reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/47/2815\" title=\"figure 1\">",
"      Solute and urine output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/20/13645\" title=\"figure 2\">",
"      Free water clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/55/15229\" title=\"figure 3\">",
"      Free water reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43518\" title=\"figure 4\">",
"      Determinants of plasma sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/25/5531\" title=\"table 1\">",
"      ADH and urine volume",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=related_link\">",
"      Chapter 10A: Acids and bases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21368?source=related_link\">",
"      Chapter 2E: Clinical evaluation of the renal circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12662?source=related_link\">",
"      Chapter 7A: Exchange of water between the cells and ECF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_52_2887="Medial retraction thyroid";
var content_f2_52_2887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Medial retraction thyroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medial retraction of thyroid with index finger covered with surgical sponge, and peanut for blunt lateral dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2887=[""].join("\n");
var outline_f2_52_2887=null;
var title_f2_52_2888="Gastric B cell lymphoma CPC Light";
var content_f2_52_2888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric B cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimens of a gastric mass showing diffuse large B cell lymphoma. This lesion may arise as transformation from MALT lymphoma or de novo. The majority are single lesions, most involve the muscularis propria, and there is a male predominance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2888=[""].join("\n");
var outline_f2_52_2888=null;
var title_f2_52_2889="Prophylaxis against Pneumocystis infection in HIV-infected patients";
var content_f2_52_2889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylaxis against Pneumocystis infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2889/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2889/contributors\">",
"     Patricia A Tietjen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2889/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2889/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/52/2889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis carinii pneumonia (PCP, but officially renamed Pneumocystis jirovecii pneumonia) remains the leading initial AIDS-defining illness and the leading cause of death due to an AIDS-related complication.",
"   </p>",
"   <p>",
"    The widespread use of PCP prophylaxis has diminished the incidence of PCP since its peak in 1988. Patients in whom the CD4 count is less than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and who are not receiving prophylaxis are nine times more likely to develop PCP within six months than individuals on therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews indications for PCP prophylaxis and recommended regimens. The presentation, diagnosis, and treatment of PCP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of PCP in patients with HIV infection include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of previous PCP",
"     </li>",
"     <li>",
"      A depressed CD4 count; approximately 95 percent of cases occur in patients with a CD4 count under 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Recurrent undiagnosed fever, night sweats, oropharyngeal thrush, and unintentional weight loss among persons with CD4 counts above 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS OF PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients not receiving antiretroviral therapy (ART), the risk of PCP without prophylaxis is 60 to 70 percent per year in patients with prior PCP and 40 to 50 percent per year in those with a CD4 cell count below 100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Prophylaxis against PCP reduces the risk of developing PCP ninefold among patients with CD4 counts below 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/1\">",
"     1",
"    </a>",
"    ]. The average CD4 count for the first episode of PCP is about 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for patients not receiving PCP prophylaxis compared to about 20",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for those receiving prophylaxis. The major reasons for failure of prophylaxis are a very low CD4 count (below 50",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    or nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis reduces the mortality rate due to PCP among patients with AIDS who develop the infection. As an example, in one series the mortality rate for AIDS patients hospitalized with PCP was lowered by approximately one-half in patients who had received prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP prophylaxis is also associated with economic benefits. A retrospective analysis of HIV-infected patients with confirmed PCP at Johns Hopkins Hospital showed that among 79 cases of PCP diagnosed in 1991, all lethal cases, 85 percent of healthcare costs, and all intensive care unit admissions occurred in patients who did not receive prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/6\">",
"     6",
"    </a>",
"    ]. Extrapolation of these data suggested that in Maryland any form of PCP prophylaxis would yield an average saving of 60 lives per year and $5 million in healthcare costs per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the current CDC guidelines that any of the following are indications for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of PCP",
"     </li>",
"     <li>",
"      CD4 cell count below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      History of oropharyngeal candidiasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who have responded to antiretroviral therapy (ART), generally only a CD4 cell count below 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or the development of PCP at a higher CD4 count while on ART are indications for prophylaxis; most patients who respond to ART do not require continuing prophylaxis for PCP (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Discontinuation of prophylaxis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is the preferred agent for PCP prophylaxis. Other prophylactic regimens are used in patients unable to tolerate TMP-SMX (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Comparative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early trial demonstrated a significant survival advantage with primary TMP-SMX PCP prophylaxis (mean survival 23 versus 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/7\">",
"     7",
"    </a>",
"    ]. Subsequent studies have dealt primarily with the relative merits of different regimens.",
"   </p>",
"   <p>",
"    Trials comparing agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared aerosolized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      (AP) 300 mg per month with TMP-SMX (either one single strength [SS] or one double strength [DS] tablet daily) in 215 HIV-infected patients with CD4 cell counts below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and no prior history of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/8\">",
"       8",
"      </a>",
"      ]. After a mean follow-up of nine months, none of the 142 patients taking TMP-SMX (either SS or DS) developed PCP, compared with 6 of 71 patients (8 percent) using AP. Adverse events requiring discontinuation of medication were much more frequent with TMP-SMX SS and TMP-SMX DS than with AP (24 and 25 versus 3 percent).",
"     </li>",
"     <li>",
"      A randomized trial with a median follow-up of 17.4 months compared AP 300 mg every four weeks with TMP-SMX (one DS tablet daily) in 310 HIV-infected patients with a prior episode of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/9\">",
"       9",
"      </a>",
"      ]. The estimated 18-month recurrence rate was lower with TMP-SMX (11 versus 28 percent). One recurrence in the AP group was extrapulmonary.",
"     </li>",
"     <li>",
"      A randomized trial with a median follow-up of 39 months compared TMP-SMX (one DS tablet daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (50 mg twice daily), and AP (300 mg every four weeks) in 843 HIV-infected patients with CD4 cell counts below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and no prior history of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/10\">",
"       10",
"      </a>",
"      ]. In an intention to treat analysis, the estimated risks of developing PCP over 36 months were similar in the three groups (18, 17, and 21 percent respectively), however only 23 percent of patients were receiving their assigned drug and dose when they completed the study. In an \"on treatment\" analysis, the estimated yearly rates of PCP among patients receiving their full dose of prophylaxis were 1.2, 2.6, and 5.7 percent respectively. Even in the intention-to treat-analysis, for patients with an initial CD4 count below 100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      the risk of PCP was lower with TMP-SMX or dapsone than with AP (19 and 22 versus 33 percent). AP was significantly better tolerated than the other medications. The percentage of patients completing the study receiving their originally assigned dose and medication was 21 percent for TMP-SMX, 25 percent for dapsone, and 88 percent for AP.",
"     </li>",
"     <li>",
"      A randomized trial with a mean follow-up of six months compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      100 mg twice weekly with AP 100 mg every 2 weeks in 278 patients with HIV-infection and a CD4 cell count below 250",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/11\">",
"       11",
"      </a>",
"      ]. Rates of PCP were similar in the two groups (18 versus 14 percent), but there were six cases of neurotoxoplasmosis with AP and none with dapsone.",
"     </li>",
"     <li>",
"      A 1996 meta-analysis of 35 studies of PCP prophylaxis in 6583 patients found that TMP-SMX was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      or aerosolized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      for the prevention of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/2\">",
"       2",
"      </a>",
"      ]. However, no statistically significant survival advantage for patients receiving TMP-SMX was noted when compared with those receiving alternative agents.",
"     </li>",
"     <li>",
"      A randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      1500 mg suspension daily and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      100 mg daily in 1057 patients with HIV infection (298 with a history of PCP and 759 with a CD4 cell count below 200",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      who could not tolerate TMP-SMX [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/12\">",
"       12",
"      </a>",
"      ]. After a median follow-up of 27 months, there was no significant difference between the regimens in the yearly risk of PCP (15.7 versus 18.4 percent respectively, relative risk [RR] 0.85, 95% CI 0.67-1.09) and no significant difference in the risk of death (RR 1.07, 95% CI 0.89-1.30).",
"     </li>",
"     <li>",
"      A randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      suspension (750 mg or 1500 mg daily) with AP 300 mg monthly in 549 patients with HIV infection and indications for PCP prophylaxis who were intolerant of TMP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      SMX [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/13\">",
"       13",
"      </a>",
"      ]. After a median follow-up of 11.3 months, there was no statistically significant difference in the incidence of PCP (26, 22, and 17 percent respectively) or mortality (20, 13, and 18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these trials suggest that TMP-SMX is the most effective agent for prophylaxis in patients who can tolerate it. AP is better tolerated than either TMP-SMX or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , but is less effective, particularly at low CD4 counts, and does not prevent toxoplasmosis. Dapsone is somewhat better tolerated than TMP-SMX and is more effective than AP. Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    is more limited, but it appears to have comparable efficacy to dapsone for PCP prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is the agent of choice for prophylaxis of PCP in patients who tolerate it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     Trimethoprim",
"    </a>",
"    is a dihydrofolate reductase inhibitor with greater activity against the Pneumocystis enzyme than the mammalian enzyme. Sulfamethoxazole is a dihydropteroate synthetase inhibitor; when coupled with trimethoprim, it offers synergy in eradicating P. jirovecii.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prevention of other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to anti-Pneumocystis activity, an additional benefit of TMP-SMX is a significant reduction in the rates of toxoplasmosis and bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ]. Potentially susceptible pathogens include Toxoplasma gondii, Isospora, Salmonella, Listeria, Nocardia, Legionella, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and many gram-negative bacilli.",
"   </p>",
"   <p>",
"    Toxoplasmosis is a particularly relevant issue because AIDS patients at risk for PCP may need prophylaxis against both pathogens. Risk for T. gondii is defined by positive IgG serology and a CD4 count below 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]. TMP-SMX is effective prophylaxis for both, although the dose of one DS tablet daily is preferred when there is a risk of toxoplasmosis. None of the alternative agents for PCP prophylaxis is considered adequate prophylaxis for toxoplasmosis, necessitating the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    to prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link&amp;anchor=H11#H11\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\", section on 'Toxoplasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dosing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials have compared different dosing strategies of TMP-SMX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial with a median follow-up of 376 days compared daily treatment with TMP-SMX SS and TMP-SMX DS in 260 HIV-infected patients with a CD4 cell count below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and no history of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/16\">",
"       16",
"      </a>",
"      ]. No patient in either group developed PCP. More adverse reactions that required discontinuation of TMP-SMX were seen with the DS regimen (hazard ratio 1.4, 95% CI 0.95-2.02).",
"     </li>",
"     <li>",
"      A randomized trial with a median follow-up of 22 months compared TMP-SMX DS daily with TMP-SMX DS three times per week in 2625 HIV-infected patients with a CD4 cell count below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/17\">",
"       17",
"      </a>",
"      ]. In an intention-to-treat analysis, the yearly rate of PCP was similar in the two groups (3.5 versus 4.1 percent, relative risk [RR] 0.82, 95% CI 0.69-1.09). In an \"on treatment\" analysis, the risk of PCP was lower with daily treatment (RR 0.59, 95% CI 0.37-0.95). Discontinuation due to an adverse event was more common with daily treatment (RR 2.14).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly used dosing regimen is one single-strength tablet per day. Alternative regimens include one double-strength tablet three times per week or one double-strength tablet daily. The latter regimen also affords protection against toxoplasmosis in patients who are toxoplasma seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its efficacy, side effects such as dermatologic reactions, hepatotoxicity, leukopenia, and fever can limit the use of TMP-SMX. In the pre-HAART era, reports of severe adverse effects requiring discontinuation of TMP-SMX occurred in 25 to 50 percent of patients compared to 25 to 40 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and 2 to 4 percent with AP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulfonamides should be immediately discontinued if any of the following conditions are present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent rash",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fever for more than five days",
"     </li>",
"     <li>",
"      Absolute neutrophil count &lt;500",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Signs of blistering, desquamation of the skin, or mucous membrane involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients can present with fevers and erythroderma that raise concerns for infection. The temporal relationship to initiation of TMP-SMX can be helpful in distinguishing an adverse drug reaction from infection. Approximately 40 percent of reactions that require discontinuation of TMP-SMX occur in the first month of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have an adverse reaction to TMP-SMX that is not life threatening, it is recommended to try to continue treatment if this is clinically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]. Antihistamines may be helpful in controlling minor reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who stop TMP-SMX because of an adverse reaction that is not life threatening, it is recommended to try to reintroduce TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]. A regimen of gradual dose escalation has been used to attempt to \"desensitize \" patients, using TMP-SMX pediatric suspension (TMP 8",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and SMX 40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Day 1: 1.25 mL once",
"     </li>",
"     <li>",
"      Day 2: 1.25 mL twice daily",
"     </li>",
"     <li>",
"      Day 3: 1.25 mL three times daily",
"     </li>",
"     <li>",
"      Day 4: 2.5 mL twice daily",
"     </li>",
"     <li>",
"      Day 5: 2.5 mL three times daily",
"     </li>",
"     <li>",
"      Day 6: one SS tablet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial compared the above dose escalation with immediate resumption of one TMP-SMX SS tablet daily in 190 HIV-infected patients who had previously discontinued TMP-SMX for an adverse reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/19\">",
"     19",
"    </a>",
"    ]. The trial was stopped early by a monitoring board because of a higher rate of continued prophylaxis at six months in the dose escalation group (75 versus 57 percent). Another study suggested that dose escalation may also be of benefit in patients who have not previously received TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rechallenge studies by others showed that approximately one-half of patients tolerated TMP-SMX after a two week drug holiday [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is a sulfone that is usually tolerated by persons who have adverse reactions to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dosing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual regimens for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      50 mg orally twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      100 mg orally daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    alone is probably less effective than TMP-SMX as prophylaxis for toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/22\">",
"     22",
"    </a>",
"    ]. For prevention of toxoplasmosis and PCP (generally in patients with serology positive for toxoplasmosis and a CD4 cell count below 100",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    the following regimens can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      50 mg orally daily, plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      50 mg orally weekly, plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium 25 mg orally weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      200 mg orally weekly, plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      75 mg orally weekly, plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      calcium 25 mg orally weekly",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chemical similarity between the sulfone structure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and the sulfonamides has raised concern about the possibility of cross-hypersensitivity between dapsone and TMP-SMX. However, a retrospective analysis of 75 patients with a history of adverse events from TMP-SMX suggested that only 7 percent developed similar adverse reactions to prophylactic dapsone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    include fever, rash, gastrointestinal upset, hemolytic anemia, and methemoglobinemia. All patients being considered for treatment with dapsone should be screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency because hemolytic anemia with dapsone occurs more frequently in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Aerosolized pentamidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    (AP) offers the advantage of relatively minor side effects and results in a significant decrease in the incidence of PCP at one year compared to placebo (9 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it offers no protection against toxoplasmosis or bacterial pathogens and is less effective than TMP-SMX in preventing PCP. The lesser efficacy of aerosolized pentamidine is most pronounced in patients with a CD4 count below 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Dosing regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    is 300 mg monthly via Respirgard II nebulizer, 6 mL diluent delivered at 6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    from a 50-psi compressed air source until reservoir is dry (usually about 45 minutes), with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , two puffs, to reduce cough and bronchospasm.",
"   </p>",
"   <p>",
"    More frequent treatments (every two weeks) are sometimes tried in patients who have multiple recurrent episodes of PCP on AP prophylaxis and are intolerant of other regimens.",
"   </p>",
"   <p>",
"    AP is only effective locally; if dispersal of the aerosol does not reach all portions of the lungs, those unreached areas remain at risk for PCP. The upper lobes of the lungs appear to be areas more difficult to protect with AP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of AP are cough and bronchospasm, but these can usually be controlled with the use of beta-agonists before treatment. AP is also a risk factor for the development of pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Screening precautions before administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for active tuberculosis should be performed in patients at risk before the administration of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    because of concern about transmission of tuberculosis to healthcare workers and other patients through pentamidine-induced bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Because of such concerns, aerosolized pentamidine should be administered in a negative pressure room in order to contain both aerosolized particles of the drug and any microbes that may be expectorated. In addition, employees should minimize their contact with the room during and for 30 minutes following such treatments.",
"   </p>",
"   <p>",
"    When aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    needs to be administered in an individual patient's hospital room, a HEPA-filtered containment tent (eg, a Demistifier tent) should be used and the airflow into this room should be temporarily altered to negative pressure, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Effect on clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    is only effective locally; if dispersal of the aerosol does not reach all portions of the lungs, untreated areas remain at risk for PCP. Cases of upper lobe and disseminated pneumocystosis have been reported in patients who have received aerosolized pentamidine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also reports that the diagnostic sensitivity of both sputum induction and bronchoalveolar lavage are diminished in patients receiving prophylaxis with AP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atovaquone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there were concerns about absorption with early formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    , atovaquone suspension is an effective but expensive alternative agent for PCP prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dosing regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    suspension for PCP prophylaxis is 1500 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effect is gastrointestinal distress. Rash may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative regimens are sometimes tried because of failure of prophylaxis or intolerance. The major risk factors for prophylaxis failure are a CD4 count below",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/3\">",
"     3",
"    </a>",
"    ] and discontinuation of TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other regimens that have been used include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two to four weeks",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      plus sulfadoxine",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    given as suppressive therapy for toxoplasmosis is also effective for PCP prophylaxis, although pyrimethamine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is not [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11442754\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience immune reconstitution on ART with a rise in CD4 cell count above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for more than three months can usually safely discontinue PCP prophylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A CDC retrospective review from the Adult and Adolescent Spectrum of HIV Disease Project compared the risk of PCP in two populations: Group 1 included 626 patients with CD4 counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and an increase of &gt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      to CD4 counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      on ART. Group 2 included 3497 control patients who never had a CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/31\">",
"       31",
"      </a>",
"      ]. The frequency of PCP was",
"      <span class=\"nowrap\">",
"       0.6/100",
"      </span>",
"      patients-years in Group 1 compared to",
"      <span class=\"nowrap\">",
"       0.8/100",
"      </span>",
"      patient-years in Group 2. The conclusion of the study was that the risk of PCP in patients with immune reconstitution with CD4 counts &gt;200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and no prophylaxis is actually less than the risk for patients who do not merit PCP prophylaxis by current guidelines.",
"     </li>",
"     <li>",
"      A European trial of 319 patients discontinuing primary PCP prophylaxis a median of 10 months after the initiation of ART found no cases of PCP after a median of 16 months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Swiss HIV cohort documented a similar result after stopping primary PCP prophylaxis in patients whose CD4 counts rose above 200",
"      <span class=\"nowrap\">",
"       cells/microL;",
"      </span>",
"      46 percent of patients in this trial had positive IgG antibodies to Toxoplasma gondii [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/33\">",
"       33",
"      </a>",
"      ]. No cases of PCP or toxoplasma encephalitis occurred during a median follow-up of 11 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also some limited observational data that suggest that discontinuation of PCP prophylaxis may even be safe in patients whose CD4 counts plateau at a level &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    as long as viral suppression is sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11442761\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials have also shown that PCP prophylaxis in patients with a previous history of PCP (secondary prophylaxis) can be stopped if patients have a sustained rise in CD4 counts in response to ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 325 patients, secondary prophylaxis was discontinued at a median CD4 count of 350",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and patients were followed for a median of 13 months without recording any episodes of PCP [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study included patients receiving primary and secondary prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/37\">",
"       37",
"      </a>",
"      ]. Among the 113 on secondary prophylaxis, the medication was stopped at a median CD4 count of 355",
"      <span class=\"nowrap\">",
"       cells/microL;",
"      </span>",
"      24 percent had detectable HIV RNA. No episodes of PCP occurred during a median follow-up of 12 months.",
"     </li>",
"     <li>",
"      A randomized trial looked at the safety of discontinuing secondary PCP prophylaxis in 146 patients on ART who experienced an increase in CD4 cell count to greater than 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for more than three months [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/38\">",
"       38",
"      </a>",
"      ]. There were no cases of PCP in the patients maintained on prophylaxis and two cases (one definite and one presumptive) in the 77 patients in the discontinuation arm.",
"     </li>",
"     <li>",
"      A report from the Swiss HIV Cohort Study examined the long-term safety of discontinuing secondary prophylaxis in 78 adult patients who responded to ART with an increase in CD4 cell count to at least 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and 14 percent of peripheral lymphocytes for at least 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/39\">",
"       39",
"      </a>",
"      ]. After a median follow-up 40.2 months there were no cases of recurrent PCP (0 cases per 100 person-years, 95% CI 0-1.3 cases per 100 person-years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11442768\">",
"    <span class=\"h2\">",
"     Guideline committee recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC guidelines recommend discontinuing both primary and secondary PCP prophylaxis in patients on ART who have had a rise in CD4 cell count to greater than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for more than three months. Prophylaxis should be restarted if the CD4 cell count falls below 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or if PCP occurs while on ART at a CD4 cell count above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/40\">",
"     40",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's website [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2889/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"       \"Patient information: Pneumocystis pneumonia (PCP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP remains the most common opportunistic respiratory infection in patients with HIV in the developing world. Prophylaxis for PCP can reduce the incidence of PCP and can prolong life. Prophylaxis regimens are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"UTD.htm?23/15/23804\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are not receiving ART and who have any of the following should receive PCP prophylaxis: history of PCP; CD4 count below 200",
"      <span class=\"nowrap\">",
"       cells/microL;",
"      </span>",
"      history of oropharyngeal candidiasis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving ART who have a CD4 count below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      or develop PCP at a higher CD4 count should also receive prophylaxis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred prophylactic agent is TMP-SMX DS administered daily. TMP-SMX SS administered daily and TMP-SMX DS administered three times per week are reasonable alternatives that may cause fewer adverse reactions. If clinically feasible, patients with minor reactions to TMP-SMX should be continued on therapy; antihistamines may be helpful in treating minor reactions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Trimethoprim-sulfamethoxazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have a reaction to TMP-SMX requiring cessation of therapy, but that is not life-threatening, should usually be retried on TMP-SMX after the reaction has resolved. A dose escalation regimen may allow more patients to tolerate resumption of TMP-SMX than immediate resumption of therapy at the full prophylactic dose. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rechallenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      100 mg daily (or 50 mg twice daily) is the preferred alternate regimen in patients intolerant of TMP-SMX. In patients with seropositivity to Toxoplasma, the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      to dapsone should be considered when the CD4 count falls below 100",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      Patients should be tested for G6PD deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      ) prior to initiating prophylaxis with dapsone. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dapsone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a CD4 cell count above 100",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      AP 300 mg monthly is a reasonable alternative in patients who cannot tolerate TMP-SMX or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      . AP is less effective at lower CD4 cell counts, and systemic medications are preferred in such patients. Patients receiving AP prophylaxis may have atypical presentations of PCP including extrapulmonary disease or disease confined to the upper lobes of the lungs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Aerosolized pentamidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      suspension 1500 mg daily is also an effective alternative agent. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Atovaquone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If these drugs are not tolerated, prophylaxis with other agents should be prescribed on an individualized basis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary or secondary prophylaxis for PCP can be safely discontinued in most patients receiving ART who achieve an increase in CD4 cell count to greater than 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for more than three months. If the CD4 count later falls below 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      or if PCP occurs at a higher CD4 count, PCP prophylaxis should be resumed. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Discontinuation of prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/1\">",
"      Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/2\">",
"      Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/3\">",
"      Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA 1995; 273:1197.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/MMWR/PDF/rr/rr5108.pdf (Accessed on April 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/5\">",
"      Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992; 152:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/6\">",
"      Gallant JE, McAvinue SM, Moore RD, et al. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 1995; 107:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/7\">",
"      Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/8\">",
"      Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/9\">",
"      Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/10\">",
"      Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/11\">",
"      Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996; 100:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/12\">",
"      El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/13\">",
"      Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/14\">",
"      Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/15\">",
"      Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/16\">",
"      Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995; 171:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/17\">",
"      El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999; 29:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/18\">",
"      Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/19\">",
"      Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001; 184:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/20\">",
"      Para MF, Finkelstein D, Becker S, et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000; 24:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/21\">",
"      Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/22\">",
"      Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/23\">",
"      Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991; 324:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/24\">",
"      Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995; 108:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/25\">",
"      Beck-Sagu&eacute; C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/26\">",
"      Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/27\">",
"      Jules-Elysee KM, Stover DE, Zaman MB, et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990; 112:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/28\">",
"      Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med 1989; 87:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/29\">",
"      Levine SJ, Masur H, Gill VJ, et al. Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1991; 144:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/30\">",
"      Barber BA, Pegram PS, High KP. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1996; 23:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/31\">",
"      Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/32\">",
"      Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999; 353:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/33\">",
"      Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/34\">",
"      D'Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count &lt; 200 cells/microl when viral replication is suppressed. AIDS 2007; 21:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/35\">",
"      Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count &lt;200 cells/microL? Clin Infect Dis 2010; 51:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/36\">",
"      Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/37\">",
"      Lopez Bernaldo de Quiros JC, Miro JM, Pe&ntilde;a JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/38\">",
"      Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/39\">",
"      Zellweger C, Opravil M, Bernasconi E, et al. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 2004; 18:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2889/abstract/40\">",
"      Teshale EH, Hanson DL, Wolfe MI, et al. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007; 44:879.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3708 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2889=[""].join("\n");
var outline_f2_52_2889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS FOR PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS OF PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS FOR PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Comparative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prevention of other infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dosing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dosing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Aerosolized pentamidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Dosing regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Screening precautions before administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Effect on clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atovaquone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dosing regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DISCONTINUATION OF PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11442754\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11442761\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11442768\">",
"      Guideline committee recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/15/23804\" title=\"table 1\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=related_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_52_2890="Evaluation and management of drug-resistant epilepsy";
var content_f2_52_2890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of drug-resistant epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2890/contributors\">",
"     Joseph I Sirven, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2890/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/52/2890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/52/2890/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/52/2890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epilepsy whose seizures do not successfully respond to antiepileptic drug (AED) therapy are considered to have drug-resistant epilepsy (DRE). This condition is also referred to as intractable, medically refractory, or pharmacoresistant epilepsy. As many as 20 to 40 percent of patients with epilepsy (roughly 400,000 Americans) are likely to have refractory epilepsy. The annual cost for patients with epilepsy in the United States is estimated to be approximately 12.5 billion dollars (based on a 1995 survey); DRE contributes a substantive proportion of this cost [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. People with DRE have the greatest burden of epilepsy-related disabilities, further contributing to the scope of this problem.",
"   </p>",
"   <p>",
"    Because of the need to individualize therapy, no rigid set of guidelines can be applied to determine medical intractability, however, population-based studies have provided information regarding the prognosis of DRE that are helpful in making treatment decisions. Resective surgical therapy for epilepsy has the potential to eliminate seizures in many patients with localization-related DRE.",
"   </p>",
"   <p>",
"    This topic discusses the evaluation and approach to the management of individuals with DRE. Other issues regarding the evaluation and treatment of individuals with seizures and epilepsy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, therapeutic failure of three antiepileptic drugs (AEDs) defined intractability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. With many new AEDs available in recent years, it might have been expected that more, rather than fewer, drug trials would be recommended before determining intractability. However, several prospective case series have shown that a high likelihood of medical intractability can be identified after two unsuccessful trials, as with each AED failure, the likelihood of successful treatment with other drugs diminishes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/5-13\">",
"     5-13",
"    </a>",
"    ]. As an example, in one study, 1098 adolescent and adult patients with a diagnosis of epilepsy were started de novo on AED treatment and followed up to 25 years (median of 7.5 years). With the first drug trial, 49 percent became seizure-free. A second medication trial produced remission in an additional 13 percent, while only a further 4 percent became seizure-free on a third medication regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/13\">",
"     13",
"    </a>",
"    ]. In this cohort, these patterns of AED responsiveness largely persisted over time.",
"   </p>",
"   <p>",
"    A task force of the International League against Epilepsy proposed that drug-resistant be defined as the failure of adequate trials of two tolerated, appropriately chosen and administered antiepileptic drugs (whether as monotherapy or in combination) to achieve seizure freedom [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/12\">",
"     12",
"    </a>",
"    ]. They also recommended replacing the term &ldquo;intractable&rdquo; with &ldquo;drug-resistant&rdquo; epilepsy (DRE).",
"   </p>",
"   <p>",
"    Some patients who meet this definition of DRE subsequently achieve prolonged (12 months or more) periods of seizure remission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the risk of seizure relapse in these individuals remains high, greater than 70 percent in one series.",
"   </p>",
"   <p>",
"    Frequency and severity of seizures are less commonly included in a definition of DRE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. These can vary among individuals with DRE and are important considerations when weighing treatment options. Similarly, it is important to understand the impact of seizures in the context of the individual's life, job, and other psychosocial circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/17\">",
"     17",
"    </a>",
"    ]. Even infrequent seizures can have a large impact.",
"   </p>",
"   <p>",
"    Less often considered, but also important, is the burden of adverse effects of AEDs that a patient experiences. If seizures can be controlled but only at medication doses that produce disabling side effects, then it may also be reasonable to consider that such a person has DRE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of unstandardized definitions as well as misdiagnoses, the incidence and prevalence of DRE are somewhat uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/18\">",
"     18",
"    </a>",
"    ]. Estimates of the proportion of epilepsy cases that are or become medically resistant vary between 20 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3,11,19-22\">",
"     3,11,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prospective studies have attempted to identify factors that predict the risk of DRE. These studies have varied somewhat in their sampling (population-based versus hospital-based) and whether they included children, adults, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/5\">",
"     5",
"    </a>",
"    ]. No single factor has been found to be uniquely useful in making accurate predictions. A combination of one or several of these factors may help to define those who are not likely to respond to medical treatment. [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/23\">",
"     23",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to the first AED trial is the most important and consistently cited predictive factor among both population-based and hospital-based studies and in both adult and pediatric populations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/5,6,13,23-26\">",
"       5,6,13,23-26",
"      </a>",
"      ]. While more than half of patients respond to the first AED prescribed, less than 20 percent are likely to respond to subsequent drug trials. AED failure due to lack of efficacy is a stronger predictor of DRE than failure due to intolerance or side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/11\">",
"       11",
"      </a>",
"      ]. With each number of failed AED trials, the risk of DRE increases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/11,25,27-29\">",
"       11,25,27-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A high number of seizures prior to diagnosis and treatment is another consistently identified risk factor for DRE [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/5-7,11,19,23,24,30-35\">",
"       5-7,11,19,23,24,30-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The underlying etiology and seizure classification are also important. Idiopathic syndromes, for both generalized and localization-related epilepsy, have a better prognosis than",
"      <span class=\"nowrap\">",
"       symptomatic/cryptogenic",
"      </span>",
"      epilepsy in both pediatric and adult populations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/7,11,13,15,19,24,28,30,36-40\">",
"       7,11,13,15,19,24,28,30,36-40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Certain pediatric epilepsy syndromes are almost invariably medically intractable. These include early (neonatal) myoclonic encephalopathy, early infantile epileptic encephalopathy, Lennox Gastaut syndrome, and Rasmussen encephalitis among others.",
"      <br/>",
"      <br/>",
"      Nonidiopathic localization-related epilepsy underlies more than half of the cases of DRE in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/7\">",
"       7",
"      </a>",
"      ]. Among the localization-related epilepsies, those associated with vascular lesions may be more treatment responsive than those with mesial temporal sclerosis (MTS), cortical dysgenesis, or dual pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/6,23,36-38,41\">",
"       6,23,36-38,41",
"      </a>",
"      ]. Individuals with MTS have some of the highest rates of medical intractability, 40 to 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3,6,8,37\">",
"       3,6,8,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other findings more variably associated with the risk of DRE include a presentation with status epilepticus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/7,24,27,36,39\">",
"       7,24,27,36,39",
"      </a>",
"      ], a longer duration of epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/28,30\">",
"       28,30",
"      </a>",
"      ], a family history of epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/11,19,32\">",
"       11,19,32",
"      </a>",
"      ], a history of febrile convulsions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/32\">",
"       32",
"      </a>",
"      ], and abnormal EEG findings [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/7,11,23\">",
"       7,11,23",
"      </a>",
"      ]. An abnormal neurologic examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      developmental delay are also identified as risk factors for DRE in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/19,27,31,36\">",
"       19,27,31,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some studies, but not all, suggest that age at presentation may be a factor in the development of DRE [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/6,11,23,27,35,36\">",
"       6,11,23,27,35,36",
"      </a>",
"      ]. Some pediatric studies have found that seizure onset in later childhood or adolescence appears to be more likely to be associated with DRE than seizures with onset between the ages of 5 and 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/7,31,39\">",
"       7,31,39",
"      </a>",
"      ]. Onset in the neonatal time period has been associated with DRE in at least one series [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/31\">",
"       31",
"      </a>",
"      ]. Individuals who develop epilepsy later in life (&gt;65 years) appear to be less likely to develop DRE than younger adults [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/22,42\">",
"       22,42",
"      </a>",
"      ]. The varying risk of DRE by age group likely relates to the underlying pathogenesis of epilepsy that also varies by age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The studies cited above have generally been performed in studies examining a patient's response to initial AED trials. However, a smaller percentage of patients with epilepsy enter remission early in their course and develop DRE later, after a period of remission that in some cases is a long as several years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. Factors that predict a later development of DRE are not well defined. However, this phenomenon of delayed intractability is most commonly described in the setting of mesial temporal sclerosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain why seizures are or become medically resistant in any given individual.",
"   </p>",
"   <p>",
"    Medical intractability may be a feature of epilepsy at the time of presentation or may evolve over time. Prospective studies with a long duration of follow-up suggest that 70 to 80 percent of patients retain their status as intractable versus in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/4,9,19,22,24,34,40,43-45\">",
"     4,9,19,22,24,34,40,43-45",
"    </a>",
"    ]. This means that a minority of patients with apparent DRE are subsequently able to achieve remission and also that some patients whose seizures are initially controlled will later relapse. In the latter group, medical control can be regained with subsequent drug trials in some patients, while in others, medical intractability is then permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/40,46-48\">",
"     40,46-48",
"    </a>",
"    ]. These different clinical courses may represent different mechanisms of medical intractability or pharmacoresistance.",
"   </p>",
"   <p>",
"    A delayed development of intractability is most often described with epilepsy onset in childhood, particularly with epilepsy associated with mesial temporal sclerosis (MTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/9,40,49,50\">",
"     9,40,49,50",
"    </a>",
"    ]. Accumulating evidence suggests that in some individuals, MTS is a progressive condition. Pathologic studies demonstrate an evolving process involving glial proliferation and dendritic sprouting with synaptic reorganization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/11,51\">",
"     11,51",
"    </a>",
"    ]. Longitudinal neuroimaging studies also support a progressive process [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/35,52\">",
"     35,52",
"    </a>",
"    ]. Alterations in neural circuitry conceivably may lead to an epileptic network that becomes drug resistant over time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37385?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathophysiology of seizures and epilepsy\", section on 'Consequences of repeated seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in animal models comparing drug-resistant and drug-sensitive temporal lobe epilepsy have found that the former is associated with altered expression of multidrug transporters, altered expression of AED targets, as well as morphologic alterations in the hippocampus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/29\">",
"     29",
"    </a>",
"    ]. Distinguishing which of these findings is the cause versus the effect of IE, and if it has relevance in human IE, are the subjects of ongoing investigations. As an example, one study found an association with a polymorphism in the drug transporter gene (ABCB1 or MDR1) and drug-resistant epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/54\">",
"     54",
"    </a>",
"    ], although this was not corroborated in follow-up studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Another hypothesis proposes that overexpression of these multidrug transporters is induced by recurrent seizures, potentially providing an impetus for early aggressive seizure treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/29,58\">",
"     29,58",
"    </a>",
"    ]. Other alterations, acquired or inherited, of AED absorption, metabolism, receptor-binding, and blood brain barrier permeability are also potential causes of pharmacoresistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF INTRACTABLE EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with DRE have an increased mortality rate, estimated at 1.37 per 100 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/26,61-63\">",
"     26,61-63",
"    </a>",
"    ]. The standardized mortality ratio for patients with recurrent seizures is 4.69 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/62\">",
"     62",
"    </a>",
"    ]. Individuals who become seizure free have no increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/64\">",
"     64",
"    </a>",
"    ]. Some deaths are related to the underlying cause of epilepsy (eg, cerebral neoplasm, neurodegenerative disease); other deaths are directly seizure-related, such as those that occur in the context of status epilepticus and in seizure-related accidents. Sudden unexplained death in epilepsy patients (SUDEP) is 40 times more likely among patients who continue to have seizures than in those who are seizure free [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=see_link\">",
"     \"Sudden unexpected death in epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonfatal injuries are also common in those with DRE. These include head injury, burns, and fractures, among others; most are seizure-related [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IE is also associated with disability and diminished quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/8,11,66\">",
"     8,11,66",
"    </a>",
"    ]. Examples include poor academic achievement, unemployment, and social isolation. Most patients with DRE cannot drive. In one community-based survey of people with epilepsy, those with self-reported incomplete seizure control were more likely to express concerns about the feelings of fear, their quality of life, work, adverse effects of therapy, and the stigma associated with their condition, even when their seizures were relatively infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/67\">",
"     67",
"    </a>",
"    ]. These complications of DRE result from the combined effects of recurrent seizures, AED toxicity, comorbid depression, as well as psychosocial factors such as excessive dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/8,11,66\">",
"     8,11,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Psychosocial issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient's seizures do not appear to respond to AED therapy, the clinician should reconsider the seizure classification and the appropriateness of the AED regimens that have been employed. Clinicians should also reconsider the diagnosis of epilepsy. Misdiagnosis is common; in one series, as many as 26 percent of individuals thought to have DRE were incorrectly diagnosed most often as a result of incomplete history-taking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    EEG misinterpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Apparent intractability",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate true versus apparent medical intractability. Reasons for apparent treatment failure that do not reflect intractability include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An incorrect diagnosis of seizure classification leading to incorrect drug choice. It is not uncommon for idiopathic generalized epilepsy syndromes to be unrecognized and inappropriately treated with AEDs that are more appropriate to localization-related epilepsy (",
"      <a class=\"graphic graphic_table graphicRef78021 \" href=\"UTD.htm?19/32/19979\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3\">",
"       3",
"      </a>",
"      ]. In some instances, a narrow-spectrum AED can worsen seizure frequency in individuals with generalized epilepsy. One example is when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      is prescribed for juvenile myoclonic epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/68-70\">",
"       68-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inappropriate dose. In other cases, inadequate dosing or frequency of AED dosing has led to apparent intractability [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/68\">",
"       68",
"      </a>",
"      ]. In contrast, seizures can also occur with AED toxicity. This has been described in rare cases in association with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Noncompliance. Compliance with AED is frequently imperfect. In one case series, 71 percent of patients reported at least occasional dose omissions, and 45 percent reported a seizure after a missed dose [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/71\">",
"       71",
"      </a>",
"      ]. Providing a nonjudgmental setting in which to elicit this history is important. Support from family members and physicians increases medical compliance [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3,72,73\">",
"       3,72,73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of the management of epilepsy in adults\", section on 'Noncompliance with AED therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lifestyle factors. Examples of lifestyle factors that can increase seizure frequency include recreational drug or alcohol abuse and sleep deprivation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/3,32,73\">",
"       3,32,73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychogenic nonepileptic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic nonepileptic seizure (PNES) can mimic epileptic seizures. In contrast to epileptic seizures, PNES are not associated with physiological central nervous system dysfunction but are instead psychogenically determined. PNES typically do not respond to AED therapy. While not without limitations, video-EEG monitoring is the gold standard test for the diagnosis of PNES.",
"   </p>",
"   <p>",
"    Among patients referred to epilepsy monitoring units for apparent IE, 25 to 40 percent are diagnosed with PNES [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The clinical features, diagnosis, and treatment of PNES are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other nonepileptic paroxysmal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to PNES, other nonepileptic paroxysmal events, especially syncope but also certain sleep and movement disorders, can be mistaken for epilepsy (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/68,76\">",
"     68,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DRE should have further testing to confirm the diagnosis of epilepsy and also to better define the epilepsy syndrome and underlying classification in order to best direct treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/17,77\">",
"     17,77",
"    </a>",
"    ]. In most cases, the evaluation of DRE will include video-EEG monitoring and magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Video EEG monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient video-EEG monitoring combines both a video and EEG recording of clinical events. This test is used primarily to determine whether epilepsy is the cause of recurrent seizure-like events. In some series, more than 25 percent of individuals referred for monitoring for refractory epilepsy are found to have nonepileptic events, usually psychogenic nonepileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/68\">",
"     68",
"    </a>",
"    ]. EEG monitoring can also aid in seizure classification and is used for presurgical evaluation of epilepsy patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the time a patient is considered to have IE, a magnetic resonance imaging (MRI) study will usually have been performed. In many cases, this should be repeated, particularly if the original study was unrevealing. In some cases, follow-up MRI reveals an etiology for epilepsy (such as cerebral neoplasm, autoimmune encephalitis) that was not seen on the initial study and requires specific therapies in addition to AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/78\">",
"     78",
"    </a>",
"    ]. The sensitivity of MRI for an underlying cause of epilepsy (so-called lesional epilepsy) can be substantially improved by using an epilepsy protocol; these are not routinely used outside of subspecialty epilepsy centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link&amp;anchor=H5#H5\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\", section on 'Sensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all MRI findings are relevant; isolated findings of diffuse atrophy, punctate foci of T2 signal abnormalities in the white matter, and other nonspecific findings are not known to be epileptogenic. MRI findings should be correlated with the patient's seizure semiology and EEG findings; some potentially epileptogenic lesions may be incidental.",
"   </p>",
"   <p>",
"    In the absence of a causative lesion on MRI, an epileptogenic focus can sometimes be defined in patients with localization-related epilepsy using advanced neuroimaging techniques including positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic source imaging (MSI). The choice of study often depends upon the availability and expertise at a particular center. The use of these tests is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seizure diaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, it may be helpful to have them carefully record seizures, along with other relevant information, including dietary changes, timing of medication intake of both AEDs and other drugs, amount and quality of sleep, and menstrual cycle changes. This may serve to improve compliance and may also help in identifying precipitants, such as hormonal changes associated with the menstrual cycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23480?source=see_link\">",
"     \"Catamenial epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resective epilepsy surgery is the treatment of choice for medically resistant lesional partial epilepsy as this has the most likely chance of producing remission. Further AED trials, vagal nerve stimulation, and the ketogenic diet can reduce seizure frequency and improve quality of life but are more likely to be palliative, rather than curative, treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further medications trials of AEDs in mono- or polytherapy can be of benefit in individuals with epilepsy. It is important to review past treatment trials with the patient to assess whether the dose or frequency of dosing was adequate. The appropriateness of past AED trials to the individual&rsquo;s seizure-type (",
"    <a class=\"graphic graphic_table graphicRef78021 \" href=\"UTD.htm?19/32/19979\">",
"     table 1",
"    </a>",
"    ) should also be specifically evaluated, as should compliance and any potential barriers to compliance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequential drug trials have a small likelihood of inducing remission in patients who have already failed two or more AED regimens. This approach can produce remission rates estimated at 4 to 6 percent per year, or a cumulative rate of 14 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/15,27,28,30,36,38,46\">",
"     15,27,28,30,36,38,46",
"    </a>",
"    ]. Among those who do not become seizure-free, a substantial reduction in seizure frequency is possible; in different series, 21 to 70 percent of patients achieve a 50 percent or greater reduction in seizure frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/28,30,36,79\">",
"     28,30,36,79",
"    </a>",
"    ]. Reduction in seizure severity may also improve patients&rsquo; quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/80\">",
"     80",
"    </a>",
"    ]. However, studies with long-term follow-up find that the benefit of successive drug trials is not sustained in one-fourth or more [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/46,47,79\">",
"     46,47,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Choosing an AED with a different mechanism of action than one not previously efficacious may maximize the benefit from subsequent drug trials (",
"    <a class=\"graphic graphic_table graphicRef71274 \" href=\"UTD.htm?30/0/30733\">",
"     table 3",
"    </a>",
"    ). Some suggest that drug combinations employing AEDs with different mechanisms of action may also be fruitful, although neither of these approaches has been systematically evaluated. An analysis of 70 randomized controlled trials of AEDs administered as add-on therapy in patients with refractory partial epilepsy found that differences in efficacy were of two small a magnitude to allow conclusions about which AED is more effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/81\">",
"     81",
"    </a>",
"    ]. The approach to successive drug trials is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Subsequent drug trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enrollment in clinical drug trials for investigational AEDs is a treatment option for patients who do not wish to proceed with current therapy, are not surgical candidates, or whose preference is to continue with medical management. Epilepsy centers and other neurologic centers often have several active ongoing research protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Epilepsy surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy surgery should be considered in appropriate patients with DRE when seizures are sufficiently frequent or severe as to significantly disrupt the patient's quality of life. These considerations are necessarily individualized, but in general include those seizures that impair consciousness, cause injury, and occur sufficiently frequently as to be disabling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resective epilepsy surgery has the best-established efficacy for individuals with lesional temporal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/84\">",
"     84",
"    </a>",
"    ]. Patients with concordant abnormalities in one temporal lobe on MRI and EEG have a rate of seizure remission as high as 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Patients with nonlesional temporal lobe epilepsy also have a high remission rate with surgical therapy. The efficacy is highest in patients in whom EEG and another imaging modality (eg, SPECT, PET, or MSI) reveal a consistent location of the epileptic focus.",
"   </p>",
"   <p>",
"    Neocortical focal epilepsy also responds to resective surgery. As with mesial temporal lobe epilepsy, rates of seizure remission are highest in patients who have MRI lesions that are concordant with the anatomic focus of seizure activity on EEG. However, localization using SPECT, PET,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MSI, can also define a seizure focus that when surgically removed leads to seizure remission rates that exceed 50 percent.",
"   </p>",
"   <p>",
"    Other surgical treatments (lobar and multi-lobar resections, hemispherectomy, corpus callosotomy, multiple subpial transections) are sometimes employed for palliative treatment in children and sometimes adults with catastrophic epilepsy syndromes.",
"   </p>",
"   <p>",
"    Epilepsy surgery appears to be underutilized in patients with uncontrolled epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. Epilepsy surgery is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Epilepsy surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vagus nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagus nerve stimulation (VNS) has been approved for adjunctive treatment of medically intractable partial onset seizures in adults and children over 12 years of age. Approximately 30 to 40 percent of patients achieve a greater than 50 percent reduction in seizure frequency, a benefit that is sustained over time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. Serious adverse events are rare.",
"   </p>",
"   <p>",
"    VNS is a valid treatment option for patients with well-documented IE, who are either opposed to intracranial surgery, or who are not candidates for intracranial surgery, or whose seizures were not substantially improved by prior intracranial epilepsy surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Resective surgery for appropriate candidates is preferred over VNS because of the substantially greater potential for complete seizure remission.",
"   </p>",
"   <p>",
"    VNS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other stimulation approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of brain implants that provide focal electrical stimulation within the brain as a means of controlling DRE is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep brain stimulation &mdash; Subcortical stimulation paradigms have targeted the anterior and centromedian thalamic nuclei, the subthalamic nucleus, the caudate, and the cerebellum [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. Open-label and some small controlled studies have found that stimulation in these sites appears to reduce seizure frequency by 50 percent or more in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/99-102\">",
"       99-102",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a randomized clinical trial of stimulation in the anterior nucleus of the thalamus (SANTE trial) in 110 patients with drug-resistant epilepsy, stimulation therapy was associated with a 29 percent reduction in seizure frequency compared with controls; 54 percent of patients had a seizure reduction of at least 50 percent. Complex partial and &ldquo;most severe&rdquo; seizures were most significantly reduced by stimulation. Participants in the stimulated group were more likely to report depression and memory problems as adverse affects [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/103\">",
"       103",
"      </a>",
"      ]. Despite the positive results of the trial, the United States Federal Drug Administration deferred approval of the device and technique until further trials were completed. The European Union has approved use of the device and technique for refractory epilepsy in its member countries.",
"     </li>",
"     <li>",
"      Cortical stimulation &mdash; Two small controlled trials, as well as other open label studies, have found that stimulation of the hippocampus appears to reduce seizure frequency in patients with mesial temporal lobe epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/104-107\">",
"       104-107",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another approach under investigation employs a closed-loop cortical stimulation unit coupled to a seizure-detection system [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/99,100,108,109\">",
"       99,100,108,109",
"      </a>",
"      ]. Open-label studies have found that this treatment may be associated with a substantial reduction in seizure number, intensity, and duration. In a clinical trial, 191 adults with medically intractable epilepsy were randomly assigned to sham or active stimulation in response to seizure detection [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/110\">",
"       110",
"      </a>",
"      ]. After 12 weeks of therapy, the reduction in seizure frequency greater in the active compared to the sham treatment arm (37.9 versus 17.3 percent). Seizure reduction was sustained over a subsequent 84 week open label period in which all patients received active stimulation. Active treatment was also associated with improved quality of life; neither mood nor cognition was negatively impacted.",
"     </li>",
"     <li>",
"      Transcranial magnetic stimulation &mdash; Low frequency transcranial magnetic stimulation also reduces cortical excitability [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/111,112\">",
"       111,112",
"      </a>",
"      ]. Uncontrolled trials and case reports have suggested that this may reduce seizure frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/113,114\">",
"       113,114",
"      </a>",
"      ]. However, small controlled trials have had mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/115,116\">",
"       115,116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ketogenic diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ketogenic diet (high-fat, low protein) diet has demonstrated efficacy in children with IE, with more than one-third experiencing a 50 percent or greater reduction in seizures",
"   </p>",
"   <p>",
"    In two small case series of adult patients, the traditional ketogenic diet and a modified Atkins diet reduced seizure frequency by 50 percent or more in half of patients with DRE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/52/2890/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ketogenic diet is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Catamenial seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with catamenial epilepsy may benefit from specific interventions to lower seizure frequency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23480?source=see_link\">",
"     \"Catamenial epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that between 20 to 40 percent of patients with epilepsy will not have complete seizure control with antiepileptic drug (AED) therapy alone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prospective studies indicate that most patients with drug-resistant epilepsy (DRE) can be identified early in their presentation, after a failure of two AED trials. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predictors of DRE include lack of efficacy of a first AED trial, a high number of seizures prior to treatment, and a",
"      <span class=\"nowrap\">",
"       symptomatic/cryptogenic",
"      </span>",
"      rather than idiopathic epilepsy syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with DRE have an increased risk of mortality as well as other disabilities including poor academic performance, unemployment, and other lifestyle restrictions. This provides an impetus for aggressive treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications of intractable epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DRE should undergo evaluation (usually video EEG monitoring) to confirm the diagnosis of epilepsy; as many as 20 percent of patients with apparent DRE will have a nonepileptic paroxysmal disorder, usually psychogenic nonepileptic seizures. EEG monitoring can also aid in seizure classification; findings should be correlated with the clinical history. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with localization-related DRE should have a magnetic resonance imaging study (MRI) to identify a potential surgical lesion. The sensitivity of MRI can be enhanced by the use of an epilepsy MRI protocol. Other neuroimaging studies (eg, SPECT, PET) can be employed in individuals in whom MRI does not show a lesion, in whom the MRI lesion does not correspond to the EEG localization, or who have dual pathology. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgical evaluation for patients with localization-related or partial epilepsy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Magnetic resonance imaging (MRI) scan performed using an epilepsy protocol will often identify a lesion (eg, mesial temporal sclerosis, cortical dysplasia) amenable to surgical resection. The best efficacy for surgery is achieved in individuals with concordant localization of MRI and EEG abnormalities. For patients without a MRI lesion, an MRI lesion that is discordant with EEG findings, or with dual pathology, further neuroimaging studies can help identify an epileptic focus that might respond to surgical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"       \"Surgical therapy of epilepsy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link\">",
"       \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients in whom epilepsy surgery is not an option or whose seizures persist after surgery, we suggest treatment trials with other AEDs appropriate for their epilepsy syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vagus nerve stimulation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). While the chance of seizure remission with these treatments is not high, reductions in seizure frequency and improved quality of life are possible in most. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"       \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Antiepileptic drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/1\">",
"      Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/2\">",
"      Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/3\">",
"      Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/4\">",
"      Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia 2006; 47:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/5\">",
"      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/6\">",
"      Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001; 57:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/7\">",
"      Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/8\">",
"      Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol 2001; 58:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/9\">",
"      Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003; 60:186.",
"     </a>",
"    </li>",
"    <li>",
"     Kwan P, Brodie M. Issues of medical intractability for surgical candidacy. In: The treatment of epilepsy and practice, 4th, Wyllie E, Gupta A, Lachhwani D.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/11\">",
"      Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/12\">",
"      Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/13\">",
"      Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012; 78:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/14\">",
"      Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011; 52:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/15\">",
"      Gilioli I, Vignoli A, Visani E, et al. Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of \"new\" antiepileptic drugs. Epilepsia 2012; 53:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/16\">",
"      Bautista RE, Glen ET. Seizure severity is associated with quality of life independent of seizure frequency. Epilepsy Behav 2009; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/17\">",
"      Benbadis SR, Tatum WO, Vale FL. When drugs don't work: an algorithmic approach to medically intractable epilepsy. Neurology 2000; 55:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/18\">",
"      National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 1990; 264:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/19\">",
"      Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/20\">",
"      Hart YM, Shorvon SD. The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy. Epilepsy Res 1995; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/21\">",
"      Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993; 34:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/22\">",
"      Mohanraj, R, Brodie, MJ. Prediction of refractory epilepsy [abstract]. Epilepsia 2003; 44(Suppl 8):156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/23\">",
"      Bonnett L, Smith CT, Smith D, et al. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol 2012; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/24\">",
"      Sillanp&auml;&auml; M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993; 34:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/25\">",
"      Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J Pediatr 1997; 131:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/26\">",
"      Perucca P, Hesdorffer DC, Gilliam FG. Response to first antiepileptic drug trial predicts health outcome in epilepsy. Epilepsia 2011; 52:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/27\">",
"      Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/28\">",
"      Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/29\">",
"      Schmidt D, L&ouml;scher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/30\">",
"      Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/31\">",
"      Camfield C, Camfield P, Gordon K, et al. Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication. J Pediatr 1993; 122:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/32\">",
"      Hitiris N, Mohanraj R, Norrie J, et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/33\">",
"      MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/34\">",
"      Del Felice A, Beghi E, Boero G, et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 2010; 51:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/35\">",
"      Bilevicius E, Yasuda CL, Silva MS, et al. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology 2010; 75:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/36\">",
"      French JA. Refractory epilepsy: clinical overview. Epilepsia 2007; 48 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/37\">",
"      Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/38\">",
"      Liimatainen SP, Raitanen JA, Ylinen AM, et al. The benefit of active drug trials is dependent on aetiology in refractory focal epilepsy. J Neurol Neurosurg Psychiatry 2008; 79:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/39\">",
"      Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 1996; 37:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/40\">",
"      Geerts A, Brouwer O, Stroink H, et al. Onset of intractability and its course over time: the Dutch study of epilepsy in childhood. Epilepsia 2012; 53:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/41\">",
"      Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localization-related epilepsies. Seizure 2005; 14:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/42\">",
"      Stephen LJ, Kelly K, Mohanraj R, Brodie MJ. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav 2006; 8:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/43\">",
"      Sillanp&auml;&auml; M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/44\">",
"      Camfield P, Camfield C. The frequency of intractable seizures after stopping AEDs in seizure-free children with epilepsy. Neurology 2005; 64:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/45\">",
"      Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch Neurol 2009; 66:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/46\">",
"      Choi H, Heiman G, Pandis D, et al. Seizure remission and relapse in adults with intractable epilepsy: a cohort study. Epilepsia 2008; 49:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/47\">",
"      Berg AT, Levy SR, Testa FM, D'Souza R. Remission of epilepsy after two drug failures in children: a prospective study. Ann Neurol 2009; 65:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/48\">",
"      Berg AT, Vickrey BG, Testa FM, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 2006; 60:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/49\">",
"      Holmes GL, Engel J Jr. Predicting medical intractability of epilepsy in children: how certain can we be? Neurology 2001; 56:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/50\">",
"      Berg AT. The natural history of mesial temporal lobe epilepsy. Curr Opin Neurol 2008; 21:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/51\">",
"      Pitk&auml;nen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/52\">",
"      Bernhardt BC, Worsley KJ, Kim H, et al. Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology 2009; 72:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/53\">",
"      Garbelli R, Frassoni C, Condorelli DF, et al. Expression of connexin 43 in the human epileptic and drug-resistant cerebral cortex. Neurology 2011; 76:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/54\">",
"      Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/55\">",
"      Sills GJ, Mohanraj R, Butler E, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/56\">",
"      Tan NC, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/57\">",
"      Szoeke C, Sills GJ, Kwan P, et al. Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. Epilepsia 2009; 50:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/58\">",
"      Pedley TA, Hirano M. Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs? N Engl J Med 2003; 348:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/59\">",
"      Teichgr&auml;ber LA, Lehmann TN, Meencke HJ, et al. Impaired function of GABA(B) receptors in tissues from pharmacoresistant epilepsy patients. Epilepsia 2009; 50:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/60\">",
"      Toering ST, Boer K, de Groot M, et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 2009; 50:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/61\">",
"      Tomson T. Mortality in epilepsy. J Neurol 2000; 247:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/62\">",
"      Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/63\">",
"      Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenit&eacute; DG, et al. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002; 43:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/64\">",
"      Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/65\">",
"      Friedman DE, Gilliam FG. Seizure-related injuries are underreported in pharmacoresistant localization-related epilepsy. Epilepsia 2010; 51:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/66\">",
"      Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011; 52:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/67\">",
"      Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res 2000; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/68\">",
"      Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999; 92:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/69\">",
"      Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003; 79:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/70\">",
"      Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/71\">",
"      Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/72\">",
"      Kyng&auml;s H. Predictors of good compliance in adolescents with epilepsy. Seizure 2001; 10:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/73\">",
"      Schuele SU, L&uuml;ders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 7:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/74\">",
"      Szaflarski JP, Ficker DM, Cahill WT, Privitera MD. Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology 2000; 55:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/75\">",
"      Gates JR, Ramani V, Whalen S, Loewenson R. Ictal characteristics of pseudoseizures. Arch Neurol 1985; 42:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/76\">",
"      Neligan A, Holdright DR, Rugg-Gunn FJ, Sander JW. A case of mistaken mesial temporal identity. BMJ 2009; 338:b2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/77\">",
"      L&uuml;ders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/78\">",
"      Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/79\">",
"      Neligan A, Bell GS, Elsayed M, et al. Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. J Neurol Neurosurg Psychiatry 2012; 83:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/80\">",
"      Sancho J, Iv&aacute;&ntilde;ez V, Molins A, et al. Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 2010; 19:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/81\">",
"      Costa J, Fareleira F, Ascen&ccedil;&atilde;o R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011; 52:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/82\">",
"      Sperling MR, O'Connor MJ, Saykin AJ, Plummer C. Temporal lobectomy for refractory epilepsy. JAMA 1996; 276:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/83\">",
"      Engel J Jr, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003; 60:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/84\">",
"      Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/85\">",
"      Radhakrishnan K, So EL, Silbert PL, et al. Predictors of outcome of anterior temporal lobectomy for intractable epilepsy: a multivariate study. Neurology 1998; 51:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/86\">",
"      Cukiert A, Cukiert CM, Argentoni M, et al. Outcome after corticoamygdalohippocampectomy in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis without preoperative ictal recording. Epilepsia 2009; 50:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/87\">",
"      Englot DJ, Ouyang D, Garcia PA, et al. Epilepsy surgery trends in the United States, 1990-2008. Neurology 2012; 78:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/88\">",
"      Haneef Z, Stern J, Dewar S, Engel J Jr. Referral pattern for epilepsy surgery after evidence-based recommendations: a retrospective study. Neurology 2010; 75:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/89\">",
"      de Flon P, Kumlien E, Reuterwall C, Mattsson P. Empirical evidence of underutilization of referrals for epilepsy surgery evaluation. Eur J Neurol 2010; 17:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/90\">",
"      Jette N, Quan H, Tellez-Zenteno JF, et al. Development of an online tool to determine appropriateness for an epilepsy surgery evaluation. Neurology 2012; 79:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/91\">",
"      A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 1995; 45:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/92\">",
"      DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000; 41:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/93\">",
"      Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr 1999; 134:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/94\">",
"      Hosain S, Nikalov B, Harden C, et al. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/95\">",
"      Kuba R, Br&aacute;zdil M, Nov&aacute;k Z, et al. Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur J Neurol 2003; 10:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/96\">",
"      Koutroumanidis M, Binnie CD, Hennessy MJ, et al. VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects. Acta Neurol Scand 2003; 107:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/97\">",
"      Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery 2004; 55:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/98\">",
"      Fisher RS. Therapeutic devices for epilepsy. Ann Neurol 2012; 71:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/99\">",
"      Theodore WH, Fisher RS. Brain stimulation for epilepsy. Lancet Neurol 2004; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/100\">",
"      Cohen-Gadol AA, Britton JW, Wetjen NM, et al. Neurostimulation therapy for epilepsy: current modalities and future directions. Mayo Clin Proc 2003; 78:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/101\">",
"      Andrade DM, Zumsteg D, Hamani C, et al. Long-term follow-up of patients with thalamic deep brain stimulation for epilepsy. Neurology 2006; 66:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/102\">",
"      Velasco F, Velasco M, Jim&eacute;nez F, et al. Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. Neurosurgery 2000; 47:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/103\">",
"      Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010; 51:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/104\">",
"      Tellez-Zenteno JF, McLachlan RS, Parrent A, et al. Hippocampal electrical stimulation in mesial temporal lobe epilepsy. Neurology 2006; 66:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/105\">",
"      Velasco AL, Velasco F, Velasco M, et al. Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study. Epilepsia 2007; 48:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/106\">",
"      Velasco M, Velasco F, Velasco AL, et al. Subacute electrical stimulation of the hippocampus blocks intractable temporal lobe seizures and paroxysmal EEG activities. Epilepsia 2000; 41:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/107\">",
"      Vonck K, Boon P, Achten E, et al. Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. Ann Neurol 2002; 52:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/108\">",
"      Peters TE, Bhavaraju NC, Frei MG, Osorio I. Network system for automated seizure detection and contingent delivery of therapy. J Clin Neurophysiol 2001; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/109\">",
"      Osorio I, Frei MG, Sunderam S, et al. Automated seizure abatement in humans using electrical stimulation. Ann Neurol 2005; 57:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/110\">",
"      Morrell MJ, RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011; 77:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/111\">",
"      Chen R, Classen J, Gerloff C, et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997; 48:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/112\">",
"      Boroojerdi B, Prager A, Muellbacher W, Cohen LG. Reduction of human visual cortex excitability using 1-Hz transcranial magnetic stimulation. Neurology 2000; 54:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/113\">",
"      Menkes DL, Gruenthal M. Slow-frequency repetitive transcranial magnetic stimulation in a patient with focal cortical dysplasia. Epilepsia 2000; 41:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/114\">",
"      Tergau F, Naumann U, Paulus W, Steinhoff BJ. Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet 1999; 353:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/115\">",
"      Theodore WH, Hunter K, Chen R, et al. Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology 2002; 59:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/116\">",
"      Fregni F, Otachi PT, Do Valle A, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilepsy. Ann Neurol 2006; 60:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/117\">",
"      Sirven J, Whedon B, Caplan D, et al. The ketogenic diet for intractable epilepsy in adults: preliminary results. Epilepsia 1999; 40:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/52/2890/abstract/118\">",
"      Kossoff EH, Rowley H, Sinha SR, Vining EP. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008; 49:316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2214 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2890=[""].join("\n");
var outline_f2_52_2890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPLICATIONS OF INTRACTABLE EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Apparent intractability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other nonepileptic paroxysmal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Video EEG monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seizure diaries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Epilepsy surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vagus nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other stimulation approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Catamenial seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2214\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2214|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/32/19979\" title=\"table 1\">",
"      Broad versus narrow-spectrum AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 2\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/0/30733\" title=\"table 3\">",
"      AED mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23480?source=related_link\">",
"      Catamenial epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37385?source=related_link\">",
"      Pathophysiology of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=related_link\">",
"      Sudden unexpected death in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_52_2891="Sleep patterns in elderly";
var content_f2_52_2891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal changes in sleep with aging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daytime napping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocturnal awakenings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total sleep time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep efficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        REM latency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slow wave sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daytime sleep latency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2891=[""].join("\n");
var outline_f2_52_2891=null;
var title_f2_52_2892="Vaughan Williams classification of antiarrhythmic drugs";
var content_f2_52_2892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vaughan Williams classification of antiarrhythmic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IA - slows conduction velocity (less than class IC) and prolongs action potential duration (APD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Disopyramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Procainamide&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IB - has no effect on conduction velocity and may shorten APD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Lidocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mexiletine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IC - slows conduction and may prolong APD (mild)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Flecainide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Propafenone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class II - blocks beta adrenergic receptors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Beta blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - prolongs APD and has no effect on conduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Dofetilide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Ibutilide&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Sotalol*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Dronedarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IV - calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Nondihydropyridine calcium channel blockers (verapamil and dilitiazem)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     APD: action potential duration.",
"     <br>",
"      &bull; Available only in intravenous formulations.",
"      <br>",
"       * I-sotalol has beta blocking and class III activities; d-sotalol is a pure class III agent.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2892=[""].join("\n");
var outline_f2_52_2892=null;
var title_f2_52_2893="Features of genetically-determined hyper-IgM syndrome";
var content_f2_52_2893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F86094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F86094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic features of genetically-determined hyper-IgM syndrome*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of infections",
"       </td>",
"       <td class=\"subtitle1\">",
"        Autoimmunity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphoid hyperplasia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Defect of CSR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Defect of SHM",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cellular defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40L deficiency (HIGM1)",
"       </td>",
"       <td>",
"        <em>",
"         CD40LG",
"        </em>",
"       </td>",
"       <td>",
"        XL",
"       </td>",
"       <td>",
"        Bacterial, opportunistic",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40 deficiency (HIGM3)",
"       </td>",
"       <td>",
"        <em>",
"         CD40",
"        </em>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Bacterial, opportunistic",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        B cells, DC, monocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AID deficiency (HIGM2)",
"       </td>",
"       <td>",
"        <em>",
"         AICDA",
"        </em>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Bacterial",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        B cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AID deficiency, C-terminus variant",
"       </td>",
"       <td>",
"        <em>",
"         AICDA",
"        </em>",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Bacterial",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        B cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIGM4",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Bacterial",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        B cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        UNG deficiency (HIGM5)",
"       </td>",
"       <td>",
"        <em>",
"         UNG",
"        </em>",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Bacterial",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        B cells",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSR: class-switch recombination; SHM: somatic hypermutation; CD40L: CD40 ligand; HIGM: hyperimmunoglobulin M syndrome (Hyper-IgM); XL: X-linked; AR: autosomal recessive; DC: dendritic cells; AID: activation-induced cytidine deaminase; AD: autosomal dominant.",
"     <br>",
"      * Hyper-IgM syndrome may also occur in some patients with post-meiotic segregation increased 2 protein (PMS2) deficiency, NF-kappa-B essential modifier (NEMO) deficiency, ataxia-telangiectasia, or Nijmegen breakage syndrome.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Biased pattern of somatic hypermutation, in which mutations at dC/dG pairs are almost all transitions (G&gt;A and&nbsp;C&gt;T)",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2893=[""].join("\n");
var outline_f2_52_2893=null;
var title_f2_52_2894="Melanonychia drug induced";
var content_f2_52_2894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85700%7EDERM%2F85615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85700%7EDERM%2F85615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs inducing longitudinal melanonychia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chemotherapeuticals",
"       </td>",
"       <td class=\"subtitle1\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Bleomycin sulfate",
"        </p>",
"        <p>",
"         Busulfan",
"        </p>",
"        <p>",
"         Cyclophosphamide",
"        </p>",
"        <p>",
"         Dacarbazine",
"        </p>",
"        <p>",
"         Daunorubicin hydrochloride",
"        </p>",
"        <p>",
"         Doxorubicin",
"        </p>",
"        <p>",
"         Etoposide",
"        </p>",
"        <p>",
"         5-fluorouracile",
"        </p>",
"        <p>",
"         Hydroxyurea",
"        </p>",
"        <p>",
"         Imatinib",
"        </p>",
"        <p>",
"         Melphalan hydrochloride",
"        </p>",
"        <p>",
"         Methotrexate",
"        </p>",
"        <p>",
"         Nitrogen mustard",
"        </p>",
"        <p>",
"         Nitrosourea",
"        </p>",
"        <p>",
"         Tegafur",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         ACTH",
"        </p>",
"        <p>",
"         Amodiaquine",
"        </p>",
"        <p>",
"         Amorolfine",
"        </p>",
"        <p>",
"         Arsenic",
"        </p>",
"        <p>",
"         Chloroquine",
"        </p>",
"        <p>",
"         Clofazimine",
"        </p>",
"        <p>",
"         Clomipramine",
"        </p>",
"        <p>",
"         Cyclones",
"        </p>",
"        <p>",
"         Fluconazole",
"        </p>",
"        <p>",
"         Fluorides",
"        </p>",
"        <p>",
"         Gold salts",
"        </p>",
"        <p>",
"         Ibuprofen",
"        </p>",
"        <p>",
"         Ketoconazole",
"        </p>",
"        <p>",
"         Lamivudine",
"        </p>",
"        <p>",
"         Mepacrine",
"        </p>",
"        <p>",
"         Mercury",
"        </p>",
"        <p>",
"         MSH",
"        </p>",
"        <p>",
"         Minocycline",
"        </p>",
"        <p>",
"         PCB",
"        </p>",
"        <p>",
"         Phenytoin",
"        </p>",
"        <p>",
"         Phenothiazine",
"        </p>",
"        <p>",
"         Psoralen",
"        </p>",
"        <p>",
"         Roxithromycin",
"        </p>",
"        <p>",
"         Steroids",
"        </p>",
"        <p>",
"         Sulfonamide",
"        </p>",
"        <p>",
"         Thallium",
"        </p>",
"        <p>",
"         Timolol",
"        </p>",
"        <p>",
"         Zidovudine",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Longitudinal melanonychia: Conditions associated with melanocytic activation and hyperplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Melanocytic activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Physiologic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Racial melanonychia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Local and regional causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Repeated local trauma from poor footwear or overriding toes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onychotillomania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nail biting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Occupational trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carpal tunnel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dermatologic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic radiation dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Localized scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic paronychia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onychomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onychomatricoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bowen disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxoid pseudocyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subungual fibrous histiocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Verruca vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Systemic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocrine disorders (Addison disease, Cushing syndrome, Nelson syndrome, hyperthyroidism, acromegaly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcaptonuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nutritional disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemosiderosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperbilirubinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Graft vs. host disease (lichen planus-type changes accompanied by longitudinal melanonychia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Iatrogenic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phototherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-ray exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Electron beam therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Laugier-Hunziker syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peutz-Jegher syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Touraine syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Melanocytic hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Lentigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nail apparatus in-situ and invasive melanoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2894=[""].join("\n");
var outline_f2_52_2894=null;
var title_f2_52_2895="Adult humerus shaft fracture";
var content_f2_52_2895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Humerus shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a simple, slightly oblique fracture of the mid humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_52_2895=[""].join("\n");
var outline_f2_52_2895=null;
